Induction Therapy Study in Live Donor Kidney Transplant Recipients With a Positive Crossmatch
Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the anti-T cell antibody, Thymoglobulin is
a more effective induction medication than the anti-IL-2R inhibitor daclizumab, in kidney
transplant recipients who have a positive crossmatch with their live donor.